CLINICAL AND RADIOGRAPHIC OUTCOMES AT TWO YEARS AND THE EFFECT OF TOCILIZUMAB (TCZ) DISCONTINUATION FOLLOWING SUSTAINED REMISSION IN THE SECOND YEAR OF THE ACT-RAY STUDY